Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.

Cellular oncology (Dordrecht, Netherlands) - 1 Jun 2020

Gomes-Filho Sandro Mascena, Dos Santos Edmilson Ozorio, Bertoldi Ester Risério Matos, Scalabrini Luiza Coimbra, Heidrich Vitor, Dazzani Bianca, Levantini Elena, Reis Eduardo Moraes, Bassères Daniela Sanchez

Abstract excerpt

PURPOSE: Oncogenic KRAS mutations are found in over 90% of pancreatic ductal adenocarcinomas (PDACs). As yet, however, no effective therapies are available for KRAS-induced malignancies. Therefore, research aimed at the identification of KRAS targets with therapeutic potential is warranted. Our goal was to investigate Aurora A (AURKA) and targeting protein for Xklp2 (TPX2) as potential therapeutic targets in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinase A
Share to Kaplan-Meier Estimate

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Microtubule-Associated Proteins

Share to Molecular Targeted Therapy

Share to Oncogenes

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to RNA, Small Interfering

Source

Open in PubMed Open full text

Identifiers

PMID: 32193808
DOI: 10.1007/s13402-020-00498-5
PMCID: PMC12990747

Genes

KRAS
TPX2
AURKA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.PMID 32193808Read ↗

Bioinformatics and experimental validation of an AURKA/TPX2 axis as a potential target in esophageal squamous cell carcinomaSemantic proximity Read ↗

LncRNA LINC00941 Links Oncogenic KRAS Signaling to Aggressiveness and Chemoresistance in Pancreatic CancerSemantic proximity Read ↗

KRAS mutation in pancreatic cancer.Semantic proximity Read ↗

Activation of PP2A-B56α leads to aberrant EGFR signaling and proliferative phenotypes in PDACSemantic proximity Read ↗

The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancerSemantic proximity Read ↗

KRAS promotes tumor metastasis and chemoresistance by repressing RKIP via the MAPK-ERK pathway in pancreatic cancer.Semantic proximity Read ↗

The novel driver gene ASAP2 is a potential druggable target in pancreatic cancerSemantic proximity Read ↗

Decreased expression of DAB2IP in pancreatic cancer with wild-type KRAS.Semantic proximity Read ↗

Mena (ENAH) Promotes KRAS-Driven Tumor Growth and Metastatic Progression in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

The Aurora-A-Twist1 axis promotes highly aggressive phenotypes in pancreatic carcinoma.Semantic proximity Read ↗

CCAT2 is an oncogenic long non-coding RNA in pancreatic ductal adenocarcinoma.Semantic proximity Read ↗

Phosphorylation-dependent regulation of ALDH1A1 by Aurora kinase A: insights on their synergistic relationship in pancreatic cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.